Transcatheter closure of post-myocardial infarction ventricular defect: Where are we?

Since 1988, TCC of PMIVSD became an alternative treatment for anatomically suitable patients with high risk of surgical closure. TCC is less invasive but the optimal timing and technique have not developed much in the last four decades. The dismal prognosis at the contemporary sight should not be discouraged. The rapid innovation in TAVI is an example. The learning curve slopes down to the line of inertia in inaction. Some innovations have slept for centuries but their potential needs to be celebrated. The published experience of TCC of PMIVSD across the globe is limited as they are based on consensus. The experience related to clinical practice has heterogeneous topography around the globe because of the morbid pathology. The increasing number of onsite cardiothoracic wings, better imaging tools, LVADS, and ECMO, along with improvement in well matching hardware to the pathology of PMIVSD, build incremental confidence. The improved outcomes believes in the enthusiasm of closing the PMIVSD using either surgical or TCC approach and is recommended.